Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Cytori Therapeutics Inc    CYTX

Delayed Quote. Delayed  - 02/12 03:59:46 pm
0.133 USD   --.--%
02/10 CYTORI THERAPEU : Scleroderma Two Year Data to be Presented at the 4..
02/08 CYTORI THERAPEU : Reports Interim Data on U.S. Phase II Osteoarthrit..
02/04 CYTORI THERAPEU : Provides Latest Corporate Update at Source Capital..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/08/2016 02/09/2016 02/10/2016 02/11/2016 02/12/2016 Date
0.14(c) 0.1399(c) 0.14(c) 0.133(c) 0.142(c) Last
4 388 248 1 930 934 1 142 853 1 060 966 1 408 337 Volume
-21.88% -0.07% +0.07% -5.00% +6.77% Change
More quotes
Financials ($)
Sales 2015 11,2 M
EBIT 2015 -23,1 M
Net income 2015 -22,7 M
Debt 2015 -
Yield 2015 -
Sales 2016 33,0 M
EBIT 2016 -10,5 M
Net income 2016 -13,1 M
Debt 2016 -
Yield 2016 -
P/E ratio 2015 -
P/E ratio 2016
Capi. / Sales 2015 1,88x
Capi. / Sales 2016 0,64x
Capitalization 21,1 M
More Financials
Company
Cytori Therapeutics, Inc. is a late stage cell therapy company.Its develops autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions.Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally... 
More about the company
Surperformance© ratings of Cytori Therapeutics Inc
Trading Rating : Investor Rating : -
More Ratings
Latest news on CYTORI THERAPEUTICS INC
02/11 CYTORI THERAPEUTICS : Cell Therapy Safe and Potentially Effective in EU Phase I ..
02/11 CYTORI THERAPEUTICS : Provides Latest Corporate Update at Source Capital Confere..
02/10 CYTORI THERAPEUTICS : Scleroderma Two Year Data to be Presented at the 4th Syste..
02/08 CYTORI THERAPEUTICS : Reports Interim Data on U.S. Phase II Osteoarthritis Trial
02/04 CYTORI THERAPEUTICS : Provides Latest Corporate Update at Source Capital Confere..
02/04 CYTORI THERAPEUTICS : Update on Its U.S. Phase III Scleroderma Trial
02/04 CYTORI THERAPEUTICS : Notice of Delisting or Failure to Satisfy a Continued List..
02/03 CYTORI THERAPEUTICS : Cell Therapy Safe and Potentially Effective in EU Phase I ..
More news
Sector news : Medical Equipment, Supplies & Distribution - NEC
02/12 MEDTRONIC : NICE Recommends Medtronic Integrated Sensor-Augmented Insulin Pump A..
02/12 DENTSPLY : meets 4Q profit forecasts
02/12 IDEXX LABORATORIES : Announces Executive Vice President Johnny Powers to Retire ..
More sector news : Medical Equipment, Supplies & Distribution - NEC
News from SeekingAlpha
02/08 Treatment benefit of Cytori's lead product candidate unclear in mid-stage stu..
02/04 Cytori Cell Therapy Has Promising Upside In The Erectile Dysfunction Market
01/25 Cytori's late-stage slceroderma study of ECCS-50 to continue as planned
01/19 Mid-stage study underway evaluating Cytori Cell Therapy in Crohn's disease-as..
2015 PREMARKET BIOTECH DIGEST : Portola's Milestone, Shkreli Resigns, BioMarin DMD Dr..


Comments 
Advertisement
Chart CYTORI THERAPEUTICS INC
Duration : Period :
Cytori Therapeutics Inc Technical Analysis Chart | CYTX | US23283K1051 | 4-Traders
Full-screen chart
Technical analysis trends CYTORI THERAPEUTI...
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions